Clinical trial • Phase III • Endocrinology|Rare Disease
AG-181 for Phenylketonuria
Phase III trial of AG-181 for Phenylketonuria. 10 participants.
Overview
- Trial Therapeutic Area
- Endocrinology|Rare Disease
- Trial Disease
- Phenylketonuria
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 28-11-2025
- First CTIS Authorization Date
- 03-04-2026
Recruitment
- Recruitment Window Months
- 22
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 10
Poland
- Earliest CTIS Part Ii Submission Date
- 26-02-2026
- Latest Decision Or Authorization Date
- 03-04-2026
- Processing Time Days
- 36
- Number Of Sites
- 2
- Number Of Participants
- 10
Sites
- Site Name
- Centrum Wsparcia Badań Klinicznych Pomorskiego Uniwersytetu Medycznego w Szczecinie
- Principal Investigator Name
- Maria Giżewska
- Principal Investigator Email
- maria.gizewska@pum.edu.pl
- Contact Person Name
- Maria Giżewska
- Contact Person Email
- maria.gizewska@pum.edu.pl
- Site Name
- Uniwersyteckie Centrum Kliniczne
- Principal Investigator Name
- Joanna Jagłowska
- Principal Investigator Email
- jjaglowska@uck.gda.p
- Contact Person Name
- Joanna Jagłowska
- Contact Person Email
- jjaglowska@uck.gda.p
Sponsor
Primary sponsor
- Full Name
- Agios Pharmaceuticals Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- AG-181
Related trials
Other published trials that may interest you.